CSNK1A1 and ovarian carcinoma: It is of note, although selective CK1 inhibitors have not yet reached clinical trials, compounds such as PF670462 have been shown to be beneficial and are well-tolerated in vivo preclinical mouse studies 31, and thus could be used in a wide variety of WNT-driven cancers, including breast 45 and ovarian cancer (this study and 18).